Cancer, hepatitis treatments set for boost as China overhauls drugs list
Blockbuster drugs such as GlaxoSmithKline’s hepatitis drug Viread, AstraZeneca’s heart drug Brilinta and Sanofi’s chronic kidney disease drug Renvela were up for inclusion over the coming weeks, industry executives said, virtually guaranteeing an uplift in sales.
Industry insiders and analysts said oncology drugs were also likely to be added to national and regional lists. Poor access to targeted cancer drugs is a hot-button issue in China, where patients often take on crippling debts or turn to grey markets to get treatment.
Changes to the National Reimbursement Drug List (NRDL), which determines which drugs are part-sponsored by the government, will be a welcome shot in the arm for global drug companies, most of whom saw sales growth slow or contract last year in the world’s number two pharmaceutical market.
“It’s pretty much the most important list to get on. Being added can really mean sales of a drug skyrocket,” said a Shanghai-based executive at a large British drugmaker.
Inclusion on the NRDL means a drug is accessible through state insurance schemes, making it affordable to mass market consumers. Any new drug approved for sale since the last update of the list in 2009 was until now largely paid for out-of-pocket by patients.
Most additions to the list, currently just over 2,000 strong, will be traditional Chinese medicines, but roughly 130 are expected to be modern drugs.
“Inclusion on the list reduces the burden of self-pay, as drugs on the list can be reimbursed up to 80 percent depending on local implementation,” said Jordan Liu, Shanghai-based associate principal at healthcare research and services company QuintilesIMS.
An executive at another global drugmaker said the list was expected to be published in the “first few months of 2017”, though some analysts said it could be as early as the Lunar New Year holiday that starts later this week. There could be a further negotiation period for high-priced drugs.
Drug companies have spent months lobbying government advisory committees to get their drugs on the NRDL, executives said. The experts on these committees vote for which drugs to include.
The Ministry of Human Resources and Social Security (MOHRSS) and the finance ministry are then involved in a final decision, based on factors including clinical need and cost – though several industry insiders said the process was opaque and the measures used to judge criteria such as clinical effectiveness were unclear.
Even once on the NRDL, drug makers negotiate pricing and access for their drug on separate provincial lists.
Access to the country’s main lists – which includes the NRDL along with the Essential Drug List (EDL) for the most critical drugs – also comes with strings attached.
Drugmakers often have to cut prices steeply to be included, helping China’s drive to lower drug prices and rein in a healthcare bill McKinsey estimates hitting $1 trillion by 2020.
“To gain market access, it’s crucial for companies to be able to show the value of their therapies in terms of improved outcomes and optimized overall cost-of-care,” added QuintilesIMS’s Liu.
GlaxoSmithKline agreed to a 67 percent cut to the price of hepatitis B drug Viread in May, eyeing in return a major volume boost. GSK declined to comment for this story. –Reuters